Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ming-Qing Du

Showing results (111-120 of 126) with videos related to

Pageof 13
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2018
Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to TherapyChulin Sha, Sharon Barrans, Francesco Cucco, et al.
The Lancet. Oncology|April 6, 2019
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trialAndrew Davies, Thomas E Cummin, Sharon Barrans, et al.
Trials|March 4, 2011
The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessmentsPeter Connick, Madhan Kolappan, Rickie Patani, et al.
The Journal of Pathology|December 21, 2019
Angioimmunoblastic T-cell lymphoma contains multiple clonal T-cell populations derived from a common TET2 mutant progenitor cellWen-Qing Yao, Fangtian Wu, Wenyan Zhang, et al.
The Journal of Pathology. Clinical Research|June 28, 2016
The prognosis of <i>MYC</i> translocation positive diffuse large B-cell lymphoma depends on the second hitAlexandra Clipson, Sharon Barrans, Naiyan Zeng, et al.
Leukemia|January 6, 2024
Non-IG::MYC in diffuse large B-cell lymphoma confers variable genomic configurations and MYC transactivation potentialChunye Zhang, Ellen Stelloo, Sharon Barrans, et al.
The Journal of Pathology|October 6, 2025
Mutation profiling in differential diagnosis between TdT-positive high-grade/large B-cell lymphoma and B-lymphoblastic leukaemia/lymphomaMaria-Myrsini Tzioni, Francesco Cucco, Lívia Rásó-Barnett, et al.
Histopathology|March 21, 2013
Another look at follicular lymphoma: immunophenotypic and molecular analyses identify distinct follicular lymphoma subgroupsTeresa Marafioti, Christiane Copie-Bergman, Maria Calaminici, et al.
Nature Genetics|December 23, 2015
Recurrent mTORC1-activating RRAGC mutations in follicular lymphomaJessica Okosun, Rachel L Wolfson, Jun Wang, et al.
Molecular Cell|August 26, 2021
Sequential inverse dysregulation of the RNA helicases DDX3X and DDX3Y facilitates MYC-driven lymphomagenesisChun Gong, Joanna A Krupka, Jie Gao, et al.
Pageof 13

Showing results (111-120 of 126) with videos related to

Sort By:
Pageof 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2018
Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to TherapyChulin Sha, Sharon Barrans, Francesco Cucco, et al.
The Lancet. Oncology|April 6, 2019
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trialAndrew Davies, Thomas E Cummin, Sharon Barrans, et al.
Trials|March 4, 2011
The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessmentsPeter Connick, Madhan Kolappan, Rickie Patani, et al.
The Journal of Pathology|December 21, 2019
Angioimmunoblastic T-cell lymphoma contains multiple clonal T-cell populations derived from a common TET2 mutant progenitor cellWen-Qing Yao, Fangtian Wu, Wenyan Zhang, et al.
The Journal of Pathology. Clinical Research|June 28, 2016
The prognosis of <i>MYC</i> translocation positive diffuse large B-cell lymphoma depends on the second hitAlexandra Clipson, Sharon Barrans, Naiyan Zeng, et al.
Leukemia|January 6, 2024
Non-IG::MYC in diffuse large B-cell lymphoma confers variable genomic configurations and MYC transactivation potentialChunye Zhang, Ellen Stelloo, Sharon Barrans, et al.
The Journal of Pathology|October 6, 2025
Mutation profiling in differential diagnosis between TdT-positive high-grade/large B-cell lymphoma and B-lymphoblastic leukaemia/lymphomaMaria-Myrsini Tzioni, Francesco Cucco, Lívia Rásó-Barnett, et al.
Histopathology|March 21, 2013
Another look at follicular lymphoma: immunophenotypic and molecular analyses identify distinct follicular lymphoma subgroupsTeresa Marafioti, Christiane Copie-Bergman, Maria Calaminici, et al.
Nature Genetics|December 23, 2015
Recurrent mTORC1-activating RRAGC mutations in follicular lymphomaJessica Okosun, Rachel L Wolfson, Jun Wang, et al.
Molecular Cell|August 26, 2021
Sequential inverse dysregulation of the RNA helicases DDX3X and DDX3Y facilitates MYC-driven lymphomagenesisChun Gong, Joanna A Krupka, Jie Gao, et al.
Pageof 13